Should I Buy BEAT? BEAT 2026 Analysis

Should You Buy Heartbeam Inc (BEAT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

1.510

1 Day change

-7.93%

52 Week Range

4.000

Analysis Updated At

2026/01/28

BEAT is not a good buy right now for a beginner, long-term investor with $50k–$100k who wants to act immediately. The stock is trading in a weak downtrend with no confirming catalyst/news this week, the company remains pre-revenue, and there are no proprietary buy signals today. Best stance is to hold off (stay on the sidelines) until a clear FDA/commercial milestone is actually announced and the chart reclaims key resistance levels.

Technical Analysis

Price/Trend: BEAT is at $1.72 (-3.65% today), trading below S1 support (1.782) and above S2 (1.601), indicating it has slipped under a key level and is testing a lower support zone. Momentum: MACD histogram is negative (-0.101) but “negatively contracting,” which suggests bearish momentum is still present but may be easing. RSI: RSI(6) ~20.9 is oversold (sub-30), implying selling pressure may be stretched, but oversold alone is not a durable long-term entry signal. Moving Averages: Converging MAs point to potential basing, but no confirmed uptrend yet. Levels to watch: Near-term downside support ~1.60; upside levels to regain are Pivot 2.074 then R1 2.366. **Intellectia Proprietary Trading Signals** - [AI Stock Picker](module://ai_stock_pick): No signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock today.

Options Data

Positive Catalysts

Potential near-term regulatory catalyst: Roth Capital expects FDA clearance in the “coming days” (per its initiation note), which could drive a sharp sentiment re-rating if confirmed.
Technical: Oversold RSI can support a short-term bounce if selling pressure fades.
Positioning: Hedge fund and insider activity are neutral (no notable recent selling pressure indicated by the provided data).

Neutral/Negative Catalysts

keeps the chart technically weak until it reclaims the pivot (2.074).

Financial Performance

Latest quarter: 2025/Q3. Revenue remained 0 (no YoY growth base). Net income improved to -$5.255M (loss narrowed ~5.5% YoY), but EPS declined to -$0.15 (worse by ~21% YoY). Overall: modest improvement in net loss, but still pre-revenue with continuing losses—limited evidence of scalable growth yet.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: Only one datapoint provided. On 2025-10-31, Roth Capital initiated coverage with a Buy and a $4 price target, based on a credit-card-sized, cable-free cardiac device and an expectation of near-term FDA clearance. Wall Street pros view (from provided coverage): Clear product narrative + anticipated regulatory milestone. Cons view (based on the rest of the provided data): The bullish thesis is not yet validated by an announced catalyst or revenue traction, and the stock’s current price action remains weak below key levels. Politicians/influential figures: No recent congress trading data available; no other influential-buy/sell data provided.

3 Analyst Rating

Wall Street analysts forecast BEAT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BEAT is 5.83 USD with a low forecast of 4 USD and a high forecast of 8 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 1.640

Low

Averages

5.83

High

Current: 1.640

Low

Averages

5.83

High

Roth Capital

NULL -> Buy

initiated

AI Analysis

2025-10-31

Reason